RCMNY
INDV icon

Rubric Capital Management (New York)’s Indivior Pharmaceuticals INDV Stock Holding History

Rubric Capital Management (New York)’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-662,515
Closed -$20.2M – 96
2026
Q1 		$20.2M Buy
662,515
+163,988
+33% +$5.42M 0.21% 66
2025
Q4 		$17.9M Sell
498,527
-632,434
-56% -$19.3M 0.21% 58
2025
Q3 		$27.3M Sell
1,130,961
-3,516,218
-76% -$73.6M 0.31% 52
2025
Q2 		$68.5M Buy
4,647,179
+1,117,140
+32% +$13M 1.03% 27
2025
Q1 		$33.6M Buy
3,530,039
+2,170,039
+160% +$22.8M 0.6% 38
2024
Q4 		$16.9M Buy
+1,360,000
New +$14M 0.22% 51

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rubric Capital Management (New York)'s INDV Position: Q2 2026 in Review

Rubric Capital Management (New York) sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 662,515 shares — an estimated $20.2M sold.

Rubric Capital Management (New York) first reported a position in INDV in Q4 2024 and held it in 6 quarters. The position peaked at $68.5M in Q2 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Rubric Capital Management (New York) reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 662,515 Indivior Pharmaceuticals shares in Q2 2026, an estimated $20.2M.
  • Rubric Capital Management (New York) first reported a position in Indivior Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Rubric Capital Management (New York)'s Indivior Pharmaceuticals position peaked at $68.5M in Q2 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.